BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18989407)

  • 1. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].
    Watarai H; Tashiro T; Chiba T; Taniguchi M
    Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371
    [No Abstract]   [Full Text] [Related]  

  • 3. NKT cell responses to glycolipid activation.
    Tefit JN; Davies G; Serra V
    Methods Mol Biol; 2010; 626():149-67. PubMed ID: 20099127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
    Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
    J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of natural killer T cells by glycolipids.
    Tupin E; Kronenberg M
    Methods Enzymol; 2006; 417():185-201. PubMed ID: 17132506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.
    Veerapen N; Kharkwal SS; Jervis P; Bhowruth V; Besra AK; North SJ; Haslam SM; Dell A; Hobrath J; Quaid PJ; Moynihan PJ; Cox LR; Kharkwal H; Zauderer M; Besra GS; Porcelli SA
    Bioconjug Chem; 2018 Sep; 29(9):3161-3173. PubMed ID: 30085659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte.
    Rhost S; Löfbom L; Rynmark BM; Pei B; Månsson JE; Teneberg S; Blomqvist M; Cardell SL
    Eur J Immunol; 2012 Nov; 42(11):2851-60. PubMed ID: 22777932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKT cells: friend or foe during viral infections?
    Diana J; Lehuen A
    Eur J Immunol; 2009 Dec; 39(12):3283-91. PubMed ID: 19830742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vivo response of invariant natural killer T cells to glycolipid antigens.
    Parekh VV; Lalani S; Van Kaer L
    Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKT cells: T lymphocytes with innate effector functions.
    Van Kaer L
    Curr Opin Immunol; 2007 Jun; 19(3):354-64. PubMed ID: 17428648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycolipids for natural killer T cells.
    Savage PB; Teyton L; Bendelac A
    Chem Soc Rev; 2006 Sep; 35(9):771-9. PubMed ID: 16936925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
    Gerth E; Mattner J
    Front Immunol; 2019; 10():1449. PubMed ID: 31293596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iNKT cells in microbial immunity: recognition of microbial glycolipids.
    Kinjo Y; Ueno K
    Microbiol Immunol; 2011 Jul; 55(7):472-82. PubMed ID: 21434991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen recognition by CD1d-restricted NKT T cell receptors.
    Godfrey DI; Pellicci DG; Patel O; Kjer-Nielsen L; McCluskey J; Rossjohn J
    Semin Immunol; 2010 Apr; 22(2):61-7. PubMed ID: 19945889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-γ production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells.
    Ishikawa H; Tanaka K; Kutsukake E; Fukui T; Sasaki H; Hata A; Noda S; Matsumoto T
    Virology; 2010 Nov; 407(2):325-32. PubMed ID: 20855097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
    Miyake S; Yamamura T
    Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells.
    Zajonc DM; Kronenberg M
    Immunol Rev; 2009 Jul; 230(1):188-200. PubMed ID: 19594637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells.
    Sriram V; Du W; Gervay-Hague J; Brutkiewicz RR
    Eur J Immunol; 2005 Jun; 35(6):1692-701. PubMed ID: 15915536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased infiltration of CD1d and natural killer T cells in periodontal disease tissues.
    Amanuma R; Nakajima T; Yoshie H; Yamazaki K
    J Periodontal Res; 2006 Feb; 41(1):73-9. PubMed ID: 16409258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.